Mental health care company COMPASS Pathways said Monday it has received a U.S. patent for its method of treating drug-resistant depression using a psilocybin formulation.
The patent includes the use of Compass' synthesized investigational psilocybin formulation COMP360 that targets patients with treatment-resistant depression.
The company previously reported that COMP360 provoked no serious adverse events.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
COMPASS is still conducting a Phase IIb clinical trial of COMP360 in treatment-resistant depression with 216 patients.
"Too many people are suffering with treatment resistant depression. We are committed to developing innovations, such as psilocybin therapy, to address this rapidly growing problem,” George Goldsmith, CEO and co-founder of Compass, said in a statement.
“Patents help ensure sustainable funding to conduct the highest quality clinical research to bring the best new therapies to patients who urgently need them. If this research demonstrates psilocybin therapy is a safe and effective option for patients, we will price it responsibly with the goal of making it as affordable and accessible as possible."
Photo via Wikimedia.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.